Benjamin Hohl sold $296K of Enliven Therapeutics (ELVN)

Executed Mar 6, disclosed Mar 10, 4 days later.

Value, as filed

$296K

10,000 sh × $29.58

Executed

Mar 6

the trade date, as filed

Disclosed

Mar 10

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Benjamin Hohl CHIEF FINANCIAL OFFICER profile →

Benjamin Hohl (CHIEF FINANCIAL OFFICER) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $296K of ELVN (10,000 sh × $29.58, as filed), executed Mar 6.

The name

ELVN

Enliven Therapeutics, Inc. ELVN · Healthcare · 56 filings in 24 months ticker →

Healthcare · Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibito…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Benjamin Hohl in ELVN

ELVNSALE Enliven Therapeutics, Inc. $232K
6,018 sh × $38.48
Exec Oct 19
Filed Oct 21 · 5:53 PM ET ELVNSALE Enliven Therapeutics, Inc. $288K
5,729 sh across 2 lots
Exec Sep 17
Filed Sep 21 · 5:23 PM ET ELVNSALE Enliven Therapeutics, Inc. $270K
4,630 sh × $58.35
Exec Aug 17
Filed Aug 19 · 4:17 PM ET ELVNSALE Enliven Therapeutics, Inc. $275K
5,202 sh across 2 lots
Exec Jul 17
Filed Jul 21 · 5:24 PM ET ELVNSALE Enliven Therapeutics, Inc. $149K
3,401 sh × $43.86
Exec Jun 17
Filed Jun 22 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $105K
4,250 sh × $24.78
Exec Nov 27 2024
Filed Dec 2 2024 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. $160K
5,600 sh × $28.49
Exec Oct 28 2024
Filed Oct 30 2024 · 5:30 PM ET